Antibodies Present in Long-Term HIV Survivors Could Contribute to Vaccine Development, Study Says Print E-mail
  
Monday, 16 March 2009 00:00
HIV-positive people who do not develop AIDS and do not require antiretroviral medication could provide insight for new strategies in vaccine development, according to a study published Sunday in the journal Nature, London's Independent reports. Michel Nussenzweig — head of Rockefeller University's Laboratory of Molecular Immunology and author of the study — said his research aimed to harness natural mechanisms to target HIV rather than use synthetically produced antibodies, some of which have failed in earlier HIV vaccine trials.

For the study, Rockefeller University researchers examined antibodies present in the blood of six long-term HIV survivors who appeared to have a degree of natural immunity to the virus (Connor, Independent, 3/16). The researchers isolated 433 antibodies from the patients, all of which targeted HIV's protective outer coating, or "envelope." The researchers then cloned the antibodies and observed which elements of the envelope each antibody targeted and how effectively it neutralized HIV. During the research, Johannes Scheid, a doctoral student at Rockefeller University, identified a new structure on the HIV envelope that scientists previously had not recognized as an antibody target. Although the researchers determined that each antibody individually had a weak effect on HIV, they also found that the antibodies as a group effectively targeted the virus (PA/Google.com, 3/15). In addition, the researchers determined that a prototype vaccine developed from several of the antibodies can prevent the growth of HIV in human cells in a test tube.

Nussenzweig said the study identified "many different antibodies that individually have limited neutralizing ability but together are quite powerful." According to Nussenzweig, only about one in every 1,000 HIV-positive people produces the neutralizing antibodies. He said the research attempts a new approach to HIV vaccine development by "copying what exists in nature and that we know can work because of the long-term survivors." He added, "Instead of inventing something that doesn't exist, it's trying to copy something that does exist." Nussenzweig said the study's results "should make people think about what an effective vaccine should look like." According to the Independent, the researchers next plan to conduct further trials of vaccine candidates on laboratory animals and human volunteers.

The Independent also profiled Kai Brothers, a San Francisco man who has been living with HIV for 28 years without developing AIDS or requiring antiretroviral medications. The Independent reports that Brothers, who did not participate in the new study, might be one of "a few — perhaps as few as one in 5,000" — HIV-positive people who have natural immunity to the virus. Brothers said he has participated in HIV research for 10 years, adding, "I feel dedicated to giving back something because of my good fortune" (Independent, 3/16).

An abstract of the study is available online.

Report link: http://www.kaisernetwork.org/daily_reports/rep_index.cfm?DR_ID=57512
Del.icio.us     Digg This!     Facebook     Google     Reddit     Stumble It!
Last Updated ( Thursday, 19 March 2009 07:51 )
 

Please Donate!

Please make a tax deductible donation to Zephyr LTNP Foundation, a 501(c)(3) entity via Paypal. No Paypal account required.
 

CROI 2011

  • Wednesday 9th March 2011
    This is our final bulletin from CROI 2011. We hope you have found our news coverage useful. You can find all our coverage at www.aidsmap.com/croi2011, including the news reports and bulletins.We are always looking for ways of improving and developing our resources – so if you have any comments that you would like
  • Thursday 3rd March 2011
    There is increasing evidence of the transmission of HIV strains with resistance to anti-HIV drugs in low- and middle-income countries. Research in eleven sub-Saharan African countries showed that the chances of detecting transmitted resistance increased by over a third each year that a country had been scaling up HIV treatment. A separate study involving people recently diagnosed
  • Wednesday 2nd March 2011
    A new type of anti-HIV drug that targets the first step in HIV’s entry into cells has done well in a Phase IIa study. Currently known as BMS-663068, the drug was shown to be safe and to work against the virus. HIV cell entry is a three-step process. The virus must first attach to the

Follow Us

  • Facebook Page: zephyrfoundation.org
  • Twitter: zephyrfound
  • YouTube: zephyrfoundation

Controllers in Study

 Donation Thermometer
 Donation Thermometer
 Donation Thermometer
86%

Our Goal:
2000
Currently:
1725
Updated:
December 30, 2009

Current Breakdown: 505 Elite Controllers 1009 Viremic Controllers 211 Other